Alvotech SDB
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic art… Read more
Alvotech SDB (ALVO-SDB) - Net Assets
Latest net assets as of : Skr- SEK
Based on the latest financial reports, Alvotech SDB (ALVO-SDB) has net assets worth Skr- SEK as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr-) and total liabilities (Skr-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Alvotech SDB - Net Assets Trend (None–None)
This chart illustrates how Alvotech SDB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Alvotech SDB (None–None)
The table below shows the annual net assets of Alvotech SDB from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to Alvotech SDB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
Alvotech SDB Competitors by Market Cap
The table below lists competitors of Alvotech SDB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ooma Inc
NYSE:OOMA
|
$320.81 Million |
|
MayAir Technology (China) Co. Ltd. A
SHG:688376
|
$320.98 Million |
|
Cosmecca Korea Co. Ltd
KQ:241710
|
$321.00 Million |
|
Lion Travel Service Co Ltd
TW:2731
|
$321.02 Million |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
$320.56 Million |
|
Nanjing Huamai Tech Co Ltd
SHG:603042
|
$320.52 Million |
|
Deutsche Beteiligungs AG
XETRA:DBAN
|
$320.52 Million |
|
Studio Dragon Corporation
KQ:253450
|
$320.51 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Alvotech SDB's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares Alvotech SDB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Alvotech SDB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares Alvotech SDB's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Alvotech SDB (ALVO-SDB) | Skr- | N/A | N/A | $320.61 Million |
| Adventure Box Technology AB (ADVBOX) | $-6.76 Million | 0.00% | 0.00x | $8.10K |
| Spotr Group AB (SPOTR) | $13.78 Million | -134.55% | 0.75x | $496.71K |